secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0000950170-25-027337
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics reports 2024 net loss $152.1M; atacicept Phase 3 primary endpoint due Q2 2025
--------------------------------------------------------------------------------

- Net loss of $152.1M ($2.75 diluted EPS) vs $96.0M ($2.25) in 2023; cash burn $134.7M operating.
- Cash and equivalents $640.9M as of Dec 31, 2024; sufficient through potential 2026 commercial launch.
- Phase 3 ORIGIN trial primary endpoint expected Q2 2025; BLA submission for atacicept planned H2 2025.
- Expanded pipeline: atacicept in PMN, FSGS, MCD; acquired next-gen fusion protein VT-109 in 2024.
- FDA Breakthrough Therapy Designation granted for atacicept in IgAN during 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017025027337/0000950170-25-027337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017025027337/vera-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-027337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer